NASDAQ : KYMR
Kymera Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 126.63 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 10.81B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 10.98B |
| Enterprise Value | 9.41B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 85.37M |
| Shares Outstanding | 85.37M |
| Shares Change (YoY) | +17.58% |
| Shares Change (QoQ) | +1.96% |
| Owned by Insiders (%) | 1.15% |
| Owned by Institutions (%) | 90.87% |
| Float | 68.26M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 106.57 |
| Forward PS | 346.13 |
| PB Ratio | 6.69 |
| P/TBV Ratio | 6.75 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 91.22 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 11.13 |
| Quick Ratio | 10.82 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,340.70 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -27.29% |
| Return on Assets (ROA) | -17.64% |
| Return on Invested Capital (ROIC) | -18.60% |
| Return on Capital Employed (ROCE) | -24.14% |
| Weighted Average Cost of Capital (WACC) | 15.06% |
| Revenue Per Employee | $374,487 |
| Profits Per Employee | -$1.28M |
| Employee Count | 273 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.98 |
| 52-Week Price Change | +106.97% |
| 50-Day Moving Average | 115.08 |
| 200-Day Moving Average | 96.70 |
| Relative Strength Index (RSI) | 70.58 |
| Average Volume (20 Days) | 863,528 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 9.17M |
| Short Previous Month | 9.91M |
| Short % of Shares Out | 10.74% |
| Short % of Float | 13.44% |
| Short Ratio (days to cover) | 10.32 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 102.24M |
| Gross Profit | -327.75M |
| Operating Income | -404.89M |
| Pretax Income | -349.43M |
| Net Income | -349.43M |
| EBITDA | -398.48M |
| EBIT | -404.89M |
| Loss Per Share | -$3.62 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 971.21M |
| Total Debt | 76.60M |
| Net Cash | 1.57B |
| Net Cash Per Share | $18.38 |
| Equity (Book Value) | 1.61B |
| Book Value Per Share | 18.92 |
| Working Capital | 908.87M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -287.57M |
| Capital Expenditures | -1.33M |
| Depreciation & Amortization | 6.41M |
| Net Borrowing | -1.72M |
| Free Cash Flow | -288.89M |
| FCF Per Share | -$3.38 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -396.04% |
| Pretax Margin | -341.79% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -17.58% |
| Shareholder Yield | -17.58% |
| Earnings Yield | -2.82% |
| FCF Yield | -2.65% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $144.39 |
| Price Target Difference | 12.31% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 24 |
| Revenue Growth Forecast (3Y) | 0.30% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 26.32 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |